Axite has secured €250,000 in Takeoff 2 early-stage funding, a significant step forward in their journey of innovation and growth. Meanwhile, 1NA has been honored with the prestigious 2025 CES Innovation Award, recognizing their outstanding contributions to technology and health.
These milestones reflect the spirit of ambition and innovation that defines our Leiden Bio Science Park community. Congratulations to both teams—here’s to an exciting future ahead!.
If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency disorder. The resubmission of the supplemental New Drug Application (sNDA) seeks approval for dosages…
